Testosterone and Bone Health in Men

TRAVERSE trial found higher fracture rates in men randomized to testosterone — a result the review calls "unexpected"

Journal: Current Osteoporosis Reports | Published: 2026-05-16 | Type: Narrative Review | PMID: 42141303 Authors: Kafel Hussein, Basaria Shehzad (Division of Endocrinology, Diabetes and Metabolism, Brigham and Women's Hospital) Funding/COI: Not listed. Authors declare no competing interests.

Summary

This review from Brigham and Women's Hospital covers three decades of evidence on testosterone's role in male bone metabolism, population studies linking sex steroid levels to BMD, and clinical trial data on testosterone therapy. The headline finding: while testosterone replacement robustly improves BMD in men with organic hypogonadism, the large TRAVERSE trial found that men randomized to testosterone therapy had higher fracture rates than controls — a result that directly undercuts the clinical logic of treating age-related low testosterone primarily for bone protection. The authors conclude that fracture-risk management in hypogonadal men should rely on agents with demonstrated anti-fracture efficacy rather than testosterone alone.

Claims

• In population studies, low testosterone and low estradiol in men are independently associated with reduced bone mass and increased fracture risk
• Testosterone replacement in men with organic hypogonadism produces "robust improvement" in BMD — no specific effect size reported in the abstract
• In middle-aged and older men with age-related low testosterone, testosterone therapy produced only "modest increases" in BMD, primarily vertebral
• The TRAVERSE trial — the largest RCT of testosterone therapy to date — found higher fracture rates in the testosterone arm vs. placebo, an outcome the authors describe as unexpected
• Testosterone therapy has not demonstrated reduction in fracture rates across the evidence base

Study Quality

This is a narrative review, not a systematic review or meta-analysis, so it carries the methodological limitations of that format: no pre-registered search protocol, no formal risk-of-bias assessment, and no quantitative pooling of effect sizes. Selection of included trials is at the authors' discretion. That said, Basaria Shehzad is among the more credible voices in male hypogonadism research, with direct involvement in the Testosterone Trials (TTrials), which gives the authors unusually close knowledge of the primary literature.

A notable data anomaly in the source material: the Methods, Results, and Conclusion sections provided appear to be from an unrelated testosterone reference-range harmonization study (reporting 264–916 ng/dL as the normal range for healthy nonobese men aged 19–39), not from this review. That mismatch suggests a data aggregation error in the underlying feed and limits confidence in any claims tied to those sections.

Red Flags

• Narrative review format allows cherry-picking; no stated search strategy
• No effect sizes reported in the abstract for "robust" or "modest" BMD improvements — qualitative language without numbers is a yellow flag
• The full-text Methods/Results/Conclusion in the source data appear to belong to a different paper entirely (harmonization of testosterone reference ranges), raising concerns about data integrity in the pipeline
• Funding source not disclosed for the review itself
• "Robust" and "modest" are relative terms — the review's conclusions depend heavily on which trials the authors chose to emphasize

Strengths

• Covers the most clinically relevant recent data point: TRAVERSE, which enrolled thousands of men and is the most adequately powered testosterone RCT to date
• The anti-fracture efficacy conclusion is appropriately conservative and follows from the evidence as summarized
• Authors are senior endocrinologists at a major academic center with direct trial experience
• No declared competing interests, and neither author lists pharma affiliations in the abstract byline

Verdict

The TRAVERSE fracture signal is the reason to read this. Most testosterone-and-bone reviews have trended toward cautious optimism — BMD goes up, therefore bones improve. TRAVERSE complicated that narrative badly, and this review from Brigham and Women's takes the finding seriously rather than explaining it away. The paper itself is a standard narrative review with all the selection-bias caveats that entails, and the absence of reported effect sizes is irritating. But as a summary of where the evidence stands in 2026 — testosterone improves bone density in some populations, yet has not been shown to reduce fractures and may increase them — it does the job.